We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Rapid Urine Test Detects Legionella

By LabMedica International staff writers
Posted on 27 Mar 2013
The test is a single use capture immunoassay to detect Legionella pneumophila serogroup 1 in human urine specimens and consists of a conjugate tube, a test strip, and sample diluent/negative control. More...


Scientists at The Regional Laboratory of Public Health, (Haarlem, The Netherlands) evaluated an immunochromatographic urine antigen test (ICT) on 213 frozen urine samples that were unconcentrated from a sample collection of patients with and without LD that were collected between 2000 and 2011. They compared the results of the assay with another commercial test.

The test, called the TRU Legionella assay, has a conjugate tube containing a lyophilized bead of colloidal gold-linked polyclonal antibody to L. pneumophila serogroup 1 detector antibody. The test strip carries a nitrocellulose membrane with dried capture antibodies placed at a designated test line for Legionella. The test strip holder caps the conjugate tube during testing and subsequent disposal to reduce exposure to potential pathogens.

The sensitivity and specificity of the Meridian TRU Legionella assay (Meridian Bioscience; Cincinnati, OH, USA) were compared with the test results obtained by the widely used ICT assay, the Binax NOW urinary antigen test (Binax; Portland, ME, USA). Both antigen tests were performed simultaneously and the results were interpreted at 15 minutes for the Binax NOW test and at 20 minutes for Meridian TRU Legionella strip. To investigate if a prolonged incubation time would affect the sensitivity, the samples were also read at 30, 45, and 60 minutes of incubation.

The sensitivity was estimated as 73.3% for the Meridian TRU Legionella test and 76.3% for the Binax NOW urine antigen test. The specificity was 100% for both assays. There were five samples, which were positive in the Binax NOW and negative in the Meridian TRU Legionella test, and those five samples were all positive in an enzyme immunoassay-control test. After a prolonged incubation, the same five samples were also positive in the Meridian TRU Legionella test. When the tests were re-examined after 60 minutes of incubation the sensitivity of the Meridian TRU Legionella test increased to 80.6 % and to 81.3 % for the Binax NOW urine antigen test.

The authors concluded that both assays evaluated have similar performance characteristics and are suitable for the detection of L. pneumophila antigen in urine from patients suspected of having LD. As the prolongation of incubation does not affect the specificity, it is recommended that an incubation time longer than that recommended by the manufacturer be used routinely. The study was published in the March 2013 issue of the European Journal of Clinical Microbiology & Infectious Diseases.

Related Links:

Dutch Regional Laboratory of Public Health
Meridian Bioscience
Binax



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Serological Pipet Controller
PIPETBOY GENIUS
New
Toxoplasma Gondii Test
Toxo IgG ELISA
New
Vasculitis Diagnostic Test
AESKULISA Vasculitis-Screen
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: Switching to an experimental drug after liquid biopsy detection of breast cancer recurrence can improve outcomes (Photo courtesy of Shutterstock)

Treatment Switching Guided by Liquid Biopsy Blood Tests Improves Outcomes for Breast Cancer Patients

Standard treatment for patients with advanced estrogen receptor (ER)-positive, HER2-negative breast cancer, a subtype driven by estrogen receptors that fuel tumor growth, often involves aromatase inhibitors,... Read more

Pathology

view channel
Image: Microscopy image of invasive breast cancer cells degrading their underlying extracellular matrix (Photo courtesy of University of Turku)

Visualization Tool Illuminates Breast Cancer Cell Migration to Suggest New Treatment Avenues

Patients with breast cancer who progress from ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC) face a significantly worse prognosis, as metastatic disease remains incurable.... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.